Purinostat Mesylate

Tier C — Watch / trade

Purinostat Mesylate

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：HDAC

Indications (approved)：Diffuse large B-cell lymphoma, Solid tumour, Multiple myeloma, Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, B-cell lymphoma, T-cell lymphoma, 前体B-细胞成淋巴细胞白血病-淋巴瘤

Regional status

China

Phase III

2025-07-18

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Purinostat Mesylate?

Approved indications include: Diffuse large B-cell lymphoma, Solid tumour, Multiple myeloma, Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, B-cell lymphoma, T-cell lymphoma, 前体B-细胞成淋巴细胞白血病-淋巴瘤.

When does the Purinostat Mesylate patent expire?

No public expiry year is available for Purinostat Mesylate yet; this page updates once verified.

How do I get a quote for Purinostat Mesylate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-30